Geetanjali Chimote - Concepedia

Author

Geetanjali Chimote

Indian Institute of Technology Bombay

Also Known As

Chimote G, G. Chimote, Geetanjali Chimote

Publications

697

Citations

H-Index

Concepts

All Affiliations

Indian Institute of Technology Bombay Sun Pharma Advanced Research (India)Tata Memorial Hospital KU Leuven Advanced Centre for Treatment, Research and Education in Cancer

About

Geetanjali Chimote is an author at Indian Institute of Technology Bombay specializing in medicine, pharmacology, and engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	311
2	Engineering	2	2	38
3	Biochemistry	2	2	25
4	Biomolecular Engineering	1	1	27
5	Cell Biology	1	1	129

Geetanjali Chimote

Publications

671

Citations

H-Index

Page 1

	Year	Citations
Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy Sudipta Basu, Rania Harfouche, Shivani Soni, Proceedings of the National Academy of Sciences NanomedicineDrug TargetingNanotherapeuticsPolymer-drug ConjugateMedicine	2009	129
Curcuminoids-loaded liposomes in combination with arteether protects against Plasmodium berghei infection in mice N.P. Aditya, Geetanjali Chimote, Karthigayan Gunalan, Experimental Parasitology InflammationPlasmodium Berghei InfectionAntiparasitic AgentMedicineCurcuminoids-loaded Liposomes	2012	110
<i>In vitro</i> evaluation of inhalable isoniazid‐loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis Geetanjali Chimote, Rinti Banerjee Journal of Biomedical Materials Research Part B Applied Biomaterials	2010	74
Comparison of effects of anti-angiogenic agents in the zebrafish efficacy&ndash;toxicity model for translational anti-angiogenic drug discovery Geetanjali Chimote, Jayasree Sreenivasan, Nilambari Pawar, Drug Design Development and Therapy	2014	70
Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a multicenter, randomized, comparative phase II/III study Minish Jain, Smita Uday Gupte, Shekhar G. Patil, Breast Cancer Research and Treatment	2016	55
Evaluation of antitubercular drug‐loaded surfactants as inhalable drug‐delivery systems for pulmonary tuberculosis Geetanjali Chimote, Rinti Banerjee Journal of Biomedical Materials Research Part A	2008	41
Phase 1 Trial of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): Activity in CML Chronic Phase Patients Failing TKI Therapies Including Ponatinib Jörge E. Cortes, Tapan Saikia, Dong‐Wook Kim, Blood	2020	34
Lung surfactant dysfunction in tuberculosis: Effect of mycobacterial tubercular lipids on dipalmitoylphosphatidylcholine surface activity Geetanjali Chimote, Rinti Banerjee Colloids and Surfaces B Biointerfaces Pulmonary TuberculosisPulmonary SurfactantMycobacterial Tubercular LipidsLung Surfactant DysfunctionTuberculosis	2005	32
Effect of antitubercular drugs on dipalmitoylphosphatidylcholine monolayers: implications for drug loaded surfactants Geetanjali Chimote, Rinti Banerjee Respiratory Physiology & Neurobiology Proteinlipid InteractionPharmaceutical ScienceEngineeringDipalmitoylphosphatidylcholine MonolayersAntitubercular Drugs	2004	27
Molecular interactions of cord factor with dipalmitoylphosphatidylcholine monolayers: Implications for lung surfactant dysfunction in pulmonary tuberculosis Geetanjali Chimote, Rinti Banerjee Colloids and Surfaces B Biointerfaces Proteinlipid InteractionPulmonary SurfactantBiochemistryProtein FoldingCord Factor	2008	14

Page 1